Why the study?
Does intravenous nadolol confer any advantages over intravenous propranolol in its effects on renal function during hypertonic saline infusion in healthy subjects?
Does intravenous nadolol confer any advantages over intravenous propranolol in its effects on renal function during hypertonic saline infusion in healthy subjects?
In healthy volunteers, intravenous nadolol does not confer any advantage over propranolol regarding renal function during hypertonic saline infusion.
No renal advantage of nadolol over propranolol seen in healthy volunteers; leaves open effects in patients with cardiovascular or renal disease.
Intravenous loading with 500 ml of 2.7% saline increased the clearance of PAH and inulin and urine sodium excretion in 14 healthy subjects. Intravenous propranolol (0.075 and 0.15 mg/kg) did not alter PAH or inulin clearance at rest but abolished the increase expected during saline infusion. There was no consistent effect on urinary sodium excretion. Intravenous nadolol (0.05 and 0.75 mg/kg) reduced resting PAH and inulin clearances by up to 25%. Both clearances fell significantly during saline infusion but natriuresis was not significantly reduced in spite of the changes in renal function. There was no evidence from these studies in normal volunteers that nadolol confers any advantages over propranolol in its effects on renal function.
No takes yet. Share an insight, caveat, or question.
Waller et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: